TY - JOUR
T1 - The state of hypertension care in 44 low-income and middle-income countries
T2 - a cross-sectional study of nationally representative individual-level data from 1·1 million adults
AU - Geldsetzer, Pascal
AU - Manne-Goehler, Jennifer
AU - Marcus, Maja Emilia
AU - Ebert, Cara
AU - Zhumadilov, Zhaxybay
AU - Wesseh, Chea S.
AU - Tsabedze, Lindiwe
AU - Supiyev, Adil
AU - Sturua, Lela
AU - Bahendeka, Silver K.
AU - Sibai, Abla M.
AU - Quesnel-Crooks, Sarah
AU - Norov, Bolormaa
AU - Mwangi, Kibachio J.
AU - Mwalim, Omar
AU - Wong-McClure, Roy
AU - Mayige, Mary T.
AU - Martins, Joao S.
AU - Lunet, Nuno
AU - Labadarios, Demetre
AU - Karki, Khem B.
AU - Kagaruki, Gibson B.
AU - Jorgensen, Jutta M.A.
AU - Hwalla, Nahla C.
AU - Houinato, Dismand
AU - Houehanou, Corine
AU - Msaidié, Mohamed
AU - Guwatudde, David
AU - Gurung, Mongal S.
AU - Gathecha, Gladwell
AU - Dorobantu, Maria
AU - Damasceno, Albertino
AU - Bovet, Pascal
AU - Bicaba, Brice W.
AU - Aryal, Krishna K.
AU - Andall-Brereton, Glennis
AU - Agoudavi, Kokou
AU - Stokes, Andrew
AU - Davies, Justine I.
AU - Bärnighausen, Till
AU - Atun, Rifat
AU - Vollmer, Sebastian
AU - Jaacks, Lindsay M.
N1 - Funding Information:
AS reports a research grant from Johnson & Johnson for work unrelated to this manuscript. All other authors declare no competing interests.
Funding Information:
PG, JM-G, RA, and LMJ received funding from the Harvard McLennan Family Fund. TB was supported by the Alexander von Humboldt Foundation, through the Alexander von Humboldt Professor award, funded by the Federal Ministry of Education and Research. We would like to thank Clare Flanagan, Sarah Frank, Michaela Theilmann, Esther Lim, Yuanwei Xu, and Jacqueline Seiglie for help with data cleaning and translation of study documentation. We would also like to thank each of the country-level survey teams and study participants who made this analysis possible.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/8/24
Y1 - 2019/8/24
N2 - Background: Evidence from nationally representative studies in low-income and middle-income countries (LMICs) on where in the hypertension care continuum patients are lost to care is sparse. This information, however, is essential for effective targeting of interventions by health services and monitoring progress in improving hypertension care. We aimed to determine the cascade of hypertension care in 44 LMICs—and its variation between countries and population groups—by dividing the progression in the care process, from need of care to successful treatment, into discrete stages and measuring the losses at each stage. Methods: In this cross-sectional study, we pooled individual-level population-based data from 44 LMICs. We first searched for nationally representative datasets from the WHO Stepwise Approach to Surveillance (STEPS) from 2005 or later. If a STEPS dataset was not available for a LMIC (or we could not gain access to it), we conducted a systematic search for survey datasets; the inclusion criteria in these searches were that the survey was done in 2005 or later, was nationally representative for at least three 10-year age groups older than 15 years, included measured blood pressure data, and contained data on at least two hypertension care cascade steps. Hypertension was defined as a systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, or reported use of medication for hypertension. Among those with hypertension, we calculated the proportion of individuals who had ever had their blood pressure measured; had been diagnosed with hypertension; had been treated for hypertension; and had achieved control of their hypertension. We weighted countries proportionally to their population size when determining this hypertension care cascade at the global and regional level. We disaggregated the hypertension care cascade by age, sex, education, household wealth quintile, body-mass index, smoking status, country, and region. We used linear regression to predict, separately for each cascade step, a country's performance based on gross domestic product (GDP) per capita, allowing us to identify countries whose performance fell outside of the 95% prediction interval. Findings: Our pooled dataset included 1 100 507 participants, of whom 192 441 (17·5%) had hypertension. Among those with hypertension, 73·6% of participants (95% CI 72·9–74·3) had ever had their blood pressure measured, 39·2% of participants (38·2–40·3) had been diagnosed with hypertension, 29·9% of participants (28·6–31·3) received treatment, and 10·3% of participants (9·6–11·0) achieved control of their hypertension. Countries in Latin America and the Caribbean generally achieved the best performance relative to their predicted performance based on GDP per capita, whereas countries in sub-Saharan Africa performed worst. Bangladesh, Brazil, Costa Rica, Ecuador, Kyrgyzstan, and Peru performed significantly better on all care cascade steps than predicted based on GDP per capita. Being a woman, older, more educated, wealthier, and not being a current smoker were all positively associated with attaining each of the four steps of the care cascade. Interpretation: Our study provides important evidence for the design and targeting of health policies and service interventions for hypertension in LMICs. We show at what steps and for whom there are gaps in the hypertension care process in each of the 44 countries in our study. We also identified countries in each world region that perform better than expected from their economic development, which can direct policy makers to important policy lessons. Given the high disease burden caused by hypertension in LMICs, nationally representative hypertension care cascades, as constructed in this study, are an important measure of progress towards achieving universal health coverage. Funding: Harvard McLennan Family Fund, Alexander von Humboldt Foundation.
AB - Background: Evidence from nationally representative studies in low-income and middle-income countries (LMICs) on where in the hypertension care continuum patients are lost to care is sparse. This information, however, is essential for effective targeting of interventions by health services and monitoring progress in improving hypertension care. We aimed to determine the cascade of hypertension care in 44 LMICs—and its variation between countries and population groups—by dividing the progression in the care process, from need of care to successful treatment, into discrete stages and measuring the losses at each stage. Methods: In this cross-sectional study, we pooled individual-level population-based data from 44 LMICs. We first searched for nationally representative datasets from the WHO Stepwise Approach to Surveillance (STEPS) from 2005 or later. If a STEPS dataset was not available for a LMIC (or we could not gain access to it), we conducted a systematic search for survey datasets; the inclusion criteria in these searches were that the survey was done in 2005 or later, was nationally representative for at least three 10-year age groups older than 15 years, included measured blood pressure data, and contained data on at least two hypertension care cascade steps. Hypertension was defined as a systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, or reported use of medication for hypertension. Among those with hypertension, we calculated the proportion of individuals who had ever had their blood pressure measured; had been diagnosed with hypertension; had been treated for hypertension; and had achieved control of their hypertension. We weighted countries proportionally to their population size when determining this hypertension care cascade at the global and regional level. We disaggregated the hypertension care cascade by age, sex, education, household wealth quintile, body-mass index, smoking status, country, and region. We used linear regression to predict, separately for each cascade step, a country's performance based on gross domestic product (GDP) per capita, allowing us to identify countries whose performance fell outside of the 95% prediction interval. Findings: Our pooled dataset included 1 100 507 participants, of whom 192 441 (17·5%) had hypertension. Among those with hypertension, 73·6% of participants (95% CI 72·9–74·3) had ever had their blood pressure measured, 39·2% of participants (38·2–40·3) had been diagnosed with hypertension, 29·9% of participants (28·6–31·3) received treatment, and 10·3% of participants (9·6–11·0) achieved control of their hypertension. Countries in Latin America and the Caribbean generally achieved the best performance relative to their predicted performance based on GDP per capita, whereas countries in sub-Saharan Africa performed worst. Bangladesh, Brazil, Costa Rica, Ecuador, Kyrgyzstan, and Peru performed significantly better on all care cascade steps than predicted based on GDP per capita. Being a woman, older, more educated, wealthier, and not being a current smoker were all positively associated with attaining each of the four steps of the care cascade. Interpretation: Our study provides important evidence for the design and targeting of health policies and service interventions for hypertension in LMICs. We show at what steps and for whom there are gaps in the hypertension care process in each of the 44 countries in our study. We also identified countries in each world region that perform better than expected from their economic development, which can direct policy makers to important policy lessons. Given the high disease burden caused by hypertension in LMICs, nationally representative hypertension care cascades, as constructed in this study, are an important measure of progress towards achieving universal health coverage. Funding: Harvard McLennan Family Fund, Alexander von Humboldt Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85070935450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070935450&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(19)30955-9
DO - 10.1016/S0140-6736(19)30955-9
M3 - Article
C2 - 31327566
AN - SCOPUS:85070935450
SN - 0140-6736
VL - 394
SP - 652
EP - 662
JO - The Lancet
JF - The Lancet
IS - 10199
ER -